Targeting mitochondrial proteases for therapy of acute myeloid leukaemia

Xinrong Xiang; Rui Bao; Yu Wu; Youfu Luo

doi:10.1111/bph.15844

Targeting mitochondrial proteases for therapy of acute myeloid leukaemia

Br J Pharmacol. 2022 Jul;179(13):3268-3282. doi: 10.1111/bph.15844. Epub 2022 Apr 15.

Authors

Xinrong Xiang^{1

2}, Rui Bao¹, Yu Wu², Youfu Luo¹

Affiliations

¹ State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
² Department of Hematology and Hematology Research Laboratory, West China Hospital, Sichuan University, Chengdu, China.

PMID: 35352341
DOI: 10.1111/bph.15844

Abstract

Targeting cancer metabolism has emerged as an attractive approach to improve therapeutic regimens in acute myeloid leukaemia (AML). Mitochondrial proteases are closely related to cancer metabolism, but their biological functions have not been well characterized in AML. According to different categories, we comprehensively review the role of mitochondrial proteases in AML. This review highlights some 'powerful' mitochondrial protease targets, including their biological function, chemical modulators, and applicative prospect in AML.

Keywords: acute myeloid leukaemia; mitochondrial metabolism; mitochondrial proteases; oxidative phosphorylation.

Publication types

Review
Research Support, Non-U.S. Gov't

MeSH terms

Humans
Leukemia, Myeloid, Acute* / drug therapy
Leukemia, Myeloid, Acute* / metabolism
Mitochondria / metabolism
Peptide Hydrolases* / metabolism
Peptide Hydrolases* / therapeutic use

Substances

Peptide Hydrolases